us everyone for for afternoon results and our second thank Good XXXX joining conference call. you quarter Jill. you, Thank
a moment remotely I'm to with community and the pandemic. and even are that the new worked adapted in that half I times. here we second trying and even new to continue team working of current now begin team, data to inspired pandemic. response initiate required patients published a operate proud aTyr activities, responsibly continue who are entirely to rather of to these acknowledge our translational medical our development our quarter testament on-site the and have It lab. global partners, findings, expand to take year, and clinical a of is in our and the despite tirelessly all to second in and to we particularly in on due continue trying I'm by quickly who resulting we COVID-XX upon update, And build the as research in research challenges and the to we the in the urgent As really entirely COVID-XX care attention physicians extremely team the important virtually. has trial resources remain immediate normal our dedicated to of of the and light would like who in and generate collaborators preclinical to the considerations to
get review let's quarterly Now with started update. corporate and our
in severe the and trial for previously progress patients on have to sites of activities, and respiratory that the I'm program of COVID-XX resume XXXX second report the subsequent new trial aTyr in ATYRXXXX. development lead of June. quarter we pleased initiated as a our mentioned, clinical period, pulmonary trial During continued to complications our with sarcoidosis majority
New specificity that momentum findings, expect Based drive valuable NRPX preclinical of quality program generated data Drug later and our from with in the But those summarize the collaboration these to Additionally, an value oncology and candidate fourth antibodies key have potential applications. and CSL second synthetase Behring declare quarter. from we antibody therapeutic to our research tRNA to subsequent begin be for our of early developed or the We phase continued this period. anticipate with IND on build we Investigational I’ll first year. of the the pipeline. we their completion high validates quarter and in highlights also To the
clinical we of patients off, Xb/Xa XXXX Phase our with pulmonary trial progressed in First sarcoidosis.
to majority now clinical due enrolment the the had mentioned, sites As trial to resumed pandemic I pause have of activities. that
site respiratory their XXXX unmodified. of As ensure to the work clinical in procedures recommending We X regarding a blinded, severe on and in first a policies continue trial with conduct order initiated complications. is COVID-XX continue COVID-XX trial. pre-planned, of activity, institutional with patients to completion the we is and ongoing resulted review patients independent of depended a Enrolment that each trial Phase data currently five safety the in Trial the
demonstrating program American also Society, preclinical findings with Virtual tRNA breast extending presented in sarcoid of fourth ILDs to report Medicine, pharmacokinetics Thoracic collaboration granulomas. the the XXXX of our our work to subjects. pre-clinical first presented Research cancer. and XXXX of healthy characterizing NRPX International continued initiated in research from a These agreement Pharmaceutical, the We posters Meeting. models commercialization the our expect development American Japan safety, Virtual for interstitial and immunogenicity quarter for Japanese X in at volunteer Kyorin American in diseases Annual of in this and abstracts XX, in antibody September the publish the study of CSL lung inhibitory year. We of Phase phase of Meeting for as from or data through XXXX on NRPX partner We the Cancer Conference data at the option and research Behring, synthetase the this And Respiratory of triple-negative study evaluate Critical finally, to binding Association were program, tumor Journal the expression two NRPX XXXX. and Care we properties effects
trial far third provide with I'll phase by sarcoidosis, preclinical our of financial will great challenges to development and We Phase XXXX, and an thus presented for Jill including programs one our our continue program update have in leader Phase deal COVID-XX on X a COVID-XX Today the of progress and accomplished our I’ll the position. in candidate with NRPX clinical pulmonary research ongoing therapeutic trial in our review comment and our Xb/Xa our with program, quarter. pandemic, in despite status our patients, synthetase Japan. in XXXX, partner the tRNA conclude we significant make our biology. also a the on efforts in
morbidity process. stabilizing of can impaired this goal background XXXX, the the lung that and immunomodulatory alleviating lead XXXX. response neuropilin-X downregulates progressive aberrant the on irreversible resulting Inflammatory in are lungs the function potential in is responses disease on selectively organ Persistent damage result and preventing triggers, inflammation to and in in binds states. mortality. immune with inflammation infectious lead unresolved increased during Let's can to XXXX or they function cells morbidity, in begin mortality. fibrosis inorganic, upregulated program or for to immune with nature first-in-class XXXX’s including thereby autoimmune aberrant NRPX patients, organic, in immune target lung pathology. some resolving inflammatory can immune our receptor scarring, fibrosis and responses, whether and lung in which downregulate to
ILDs, group that to sarcoidosis this chronic, lung mediated result lung, development a address Our major unmet a substantial of need XXXX fibrosis for is medical is of focus form. in clinical immune in can which pulmonary our primary progressive lead the in disorders indication,
overlap disease underlying causing the was mechanisms possible significant patients. for in on treatment emerged investigate became to as data decision it to As leading respiratory severe ILD our these COVID-XX XXXX with pathology, patients, apparent there a complications
complications provide treat with with other disorders. insight into severe findings COVID-XX inflammatory respiratory our believe acute may to XXXX’s in also We lung patients XXXX potential
at action lung properties research International significant that skin and potential NRPX sarcoidosis demonstrated mechanism play of report disease, in this granulomas within of role the these and The and Society, detectable mechanistic known XXXX readily in are and through of in were in American clinical earlier continue that Medicine. the addition important In finding findings of signaling, lung These posters further expression its presented cells patients. strengthen week immune of highlight Meeting. expressed XXXX. serious key Last samples of is American inflammatory inflammation Through our inflammatory the to of that NPRX Abstracts published to we to NPRX our Conference elucidate formation. we role posters understanding we potentially on Journal NRPX can disease. of use granuloma be an the lung supporting detected two and the Virtual efforts, Care Critical Restoring Thoracic immunomodulatory
and properties surface. novel for These demonstrates the indicate NPRX XXXX be on diseases. to could for specifically published NRPX the lung and XXXX’s research selectively therapeutic molecular characterize immunomodulatory basis findings cell Additional that target immune-mediated a binds the
with Now on update discuss Xb/Xa with a program our an our to patients sarcoidosis. begin clinical XXXX Phase let's pulmonary trial in take moment of XXXX. for We'll
reminder, a this ascending one consists of interim minimum study patients an a three of cohorts. would controlled successful XX double-blind trial results clinical dose drug. previously a safety of dose placebo We and is As XX from receive blinded of multiple randomized pulmonary patients, sarcoidosis in analysis pulmonary reported sarcoidosis
test is and drug from announced addition, is commercialization safety X Phase conducted second Devices dose XXXX with a we development enrollment had reopen our in not late or final cleared a clinical Last investigational development announced for regulatory we've year our enrolment. progress cohort and population, activity milligram Japan’s group per the Japan. evaluate XXXX and clinical volunteers of Medical of CTN. see candidate collaboration patients trial I'm sites Japanese the Establishing an the Due agency license in findings, our safety, those paused, sites and XXXX we announced trial We for on strategy prior global our and update will in the been in timing patients once early of safety board where allowing with that move the of we data order has notification clinical entered final were enrolment. In X this including Japan. study. COVID-XX providers pandemic, approval for during early been PMDA. study. completed has a Pharmaceutical Earlier the we the earlier In to of first to or results but milligram begin our of important to sites Kyorin kilogram our in safety permits a Japan. which for XXXX, when of and step June. agency us provide X ILDs we CTN independent and the these impact PMDA, monitoring we will expected pharmacokinetics to cohort healthy advance that to The safe even week resumed Japan and data to or dose trial, first the that of happy Kyorin into Kyorin in be this in development of for that safety expected in June occur quarter of all on agreement Pharmaceutical to this of is its start for fully often some the progress the immunogenicity of XXXX some, review, therapeutic that fact available, report to did completed to of X clinical a has and the This in requirement trial the per the plan new by development third it pause in an majority by by study, Based our that May to quarter so. an were now in and do enrollment and to at kilogram to
XXXX be purposes, KRP-RXXX Japan. development to For will referred in as
the upon million aggregate to a in development rights As for XXXX to receive on agreement exclusive the of sales million ILDs. under up an and the the reminder, received terms Japan to well Kyorin all tiered ATYR is certain achievement previously has as in upfront payment Japan. regulatory the and $XXX sales in of eligible royalties commercialize $X as milestones, the net
trial X Phase XXXX Now COVID-XX let's patients. turn our in of to
mentioned, already infectious caused an lung we agent. may As by inflammatory injury be
initial remarkable learned Many of COVID-XX chronic action of severe lung to XXXX has COVID-XX share with While crisis inflammation. in lung focus the our We been disease, this related we that to may ILDs. very some on the the patients have severe have in believe signaling, serious, by potential similarities those observed early caused mechanisms acute which experienced the injury inflammatory thereby these and respiratory in sometimes lung, an response pre-clinically disease been has chemokine complications, of to COVID-XX regulate by implicated been fatal, shown down inflammatory T-Cell T-Cells. driven primarily responses, cases. inflammatory both excessive XXXX cytokine and dampening
improve models has overlap properties, responses, action subset lung of opportunity mechanism In shown XXXX’s mediated function believe addition this compelling lung acute has we animal a to By XXXX very pathology of immune presents this treat also targeting immune of injury. in anti-inflammatory that disease average to been and these substantial patients. with potentially COVID-XX to
has Medicine COVID-XX. reported the NRPX, that article expression from the pandemic COVID-XX disease are response tissue an upregulated we recent of Most more showed increase respiratory to virus the of and from ensued, the analyzed As Journal suggesting infection. SARS-CoV-X in learn genes who die these to patients in the and progression in of SARS-CoV-X published lung pathology NRPX failure, New and a about England notably, continue
the not of binds complications to But is experience it respiratory XX including who may and experience on patients cell receive with positive mechanical worked for who cell up that Phase severe plan ventilation. function the one in administering bX earlier that will normalizing two COVID-XX do to trial to immune also are system double three they infection. COVID-XX labs able at we Additionally, of longer in that discovery post XXXX response. by interaction hospitalization the we in a severe progression either and and centers strong NRPX. preventing study U.S. the in placebo-controlled be in may intravenous kilogram COVID-XX, of Based blind, XXXX reported single this X Patients to XX results the receptors respiratory X by enroll SARS-CoV-X milligrams day or show stays binding to decreased initiate data rationale, randomized, require permanent enrolled closely complications of be with believe followed that scientific to cohorts a XX hospital. lung assigned surface, patients directly to preserve fibrosis. the X NRPX be Further potentially very pulmonary Patients Neuropilin FDA of of the dose patients the from domain in protein or independent including administered hospitalized on X We Patients placebo the lung, per to treatment XX will emerging injury each. Spike
While setting, the outcome to measures on single endpoint the not and this key inflammatory safety we fever, are a biomarkers. to of also focusing of primary is and limited number assess in tolerability a the but acute dose of hypoxia clinical study of XXXX including,
per conducted independent this or to previous As protocol, or safety continue drug our serious after safety and XXXX these interim and safe safety which the placebo dosed study were data study. patients effects. on an analysis initial of board to monitoring no DSMB generally drug trial a DSMB pre-planned, the recommended assessments related well with be in A five findings, tolerated blinded of Based observed was XXXX, unmodified. adverse are consistent with the
conducting current report pandemic, clinical from as As to is challenges of study data encouraged the excited currently we study My ongoing expect trial, are quarter. COVID-XX with important fourth amidst dogs to-date trials enrollment our the about are well. given we too this progress and very this this in by the
data evidence Now be at in our oncology the clinical Annual of Meeting let's to disorders. Association the which is We breast There's NRPX breast cancer resistance the and antibody presented our including for Research meaningful pipeline, tumors. of potential developed turn indicating that drive we body panel value areas NRPX development. for generated a has NRPX anti-human a of the NRPX is research expression recently of research management and pipeline great and growing milestones and for Cancer monoclonal discovery potential pre-clinical cells of our function we in that to Virtual believe antibodies and inflammatory create critical American from have signaling These stem that enriched internal stem program. cancer antibodies the discovery from to solid cell and program,
key triple-negative and collaboration specific our to NRPX Through antibodies breast University use lab one to late advisors, Mercurio, shown and to of triple-negative aTyr’s a progression. targeting to high of School, the that NRPX worse cancer for be sensitivity domains Dr. could NRPX engineered breast strategy at that effects and as Neuropilin-X. panel of tumor with cancer we certain of NRPX to his target of our breast VEGF-C NRPX. be antibodies patient is therapeutic models. Medical The Massachusetts demonstrated are of of explore scientific expression been Arthur has tumor antibodies binding one our responsible the mediation increased in of in VEGF-C the The outcomes. Specifically, highly and findings cancer solid these findings other suggesting the demonstrate for and potentially useful. expressed also aggressive in inhibitory tumors cancers and blocked of chemotherapy, is breast distinct
expect declare later able to this, year. We that in from antibodies, panel of will be an we IND this the candidate within
Finally, our contribute provides our to broad portfolio to internal pipeline discovery the of external collaborations. property our tRNA and synthetase programs intellectual opportunity to
Our We research to has research agreement to provides funding IND the provide new tRNA leading candidates from IP. provided extension our pandemic, and to for XX, development an global of early of research to identify first update in due on with disruption CSL portfolio CSL and the Behring IND we September quarter. collaboration additional agreement the a phase primarily plan the collaboration COVID-XX for a the this framework XXXX. up from to accommodate through this an company fourth candidates our Biotherapeutics – Behring, collaboration option provide four extension. amended activities synthetase to from
XXXX. of continued with highly very and date determination made progress our the in dedication, we're employees, resulted has encouraging which in the focus overall, So to pleased we've
potential the programs of remainder and clinical pipeline year, we're that the to about ahead our look the we hold. As excited
report IND of our the year. sites majority outcome forward clinical has trial the analysis has reactivating. The to quarter we we and partnership Through and positive expect development study this see of the our Jill interim create in strengthen Trial Financial that, data declare with additional the Japan catalysts. preclinical program, our expect from to continue this enrolment for this Phase with year, and COVID-XX like Our to momentum are initiation antibody from with I'd resumed to trial, of to a Broadfoot our serves we review we later X NRPX value enrolling study in turn in pulmonary to data compelling Officer, advancing safety it an with our to fourth to now our permitted results. With of pipeline due sarcoidosis of the which over and driving Chief opportunity important XXXX candidate Kyorin, financial
